Xeris Biopharma Holdings Inc XERS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Xeris Announces Details for XP-8121 Program Overview Webinar
Trading Information
- Previous Close Price
- $16.70
- Day Range
- $16.39–16.94
- 52-Week Range
- $5.25–16.98
- Bid/Ask
- $16.76 / $16.86
- Shares Outstanding
- 182.70M
- Market Cap
- $3.07B
- Volume/Avg
- 3M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 279.67
- Price/Sales
- 8.43
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.08%
Company Profile
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 435
- Website
- https://www.xerispharma.com
Valuation
Metric | XERS |
|---|---|
Price/Earnings (Normalized) | 279.67 |
Price/Book Value | 62.80 |
Price/Sales | 8.43 |
Price/Cash Flow | 43.12 |
Price/Earnings
XERS
Financial Strength
Metric | XERS |
|---|---|
Quick Ratio | 1.48 |
Current Ratio | 2.15 |
Interest Coverage | 0.58 |
Quick Ratio
XERS
Profitability
Metric | XERS |
|---|---|
Return on Assets (Normalized) | 14.03% |
Return on Equity (Normalized) | 428.16% |
Return on Invested Capital (Normalized) | 28.81% |
Return on Assets
XERS
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|%^<JJ! | LOCK|^Xb%d | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|##WH^K@ | LOCK|!%vM | $49B | |||
| Haleon PLC ADR HLN | LOCK|<xt$!wK | LOCK|n& | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|>??^rR% | LOCK|NL | $34B | |||
| Viatris Inc VTRS | LOCK|K?@t^y | LOCK|MS | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|%hk | LOCK|!h% | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|HYZp!$ | LOCK|$S | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|FfKylSd | LOCK|<$ | $4B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|PbCm^Nv | LOCK|FSq%Y | $2B | |||
| Perrigo Co PLC PRGO | LOCK|r$V%N<V | LOCK|K&M | $2B |